Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This prediction still stands. RGTI is James Webb of Quantum computing and more.
funny Chinese legacy company - modest no exuberant. Obviously they control earning number, control stock price, they control ... they control their companies from backyard roasting oven..
ahh
no kidding - AEVA!!!!!!???????
ONCY earning release tomorrow - Guess it is time for them to talk more on FDA approval, launch time line and the players
"PANW reported 2nd quarter 2024 earnings of USD 1.46 per share on 2/20/24.This beat the consensus of USD 1.30 by USD 0.16 of the 38 analysts covering this company" - but even on a day like today (everything GREEN) its SP melting like a ice block placed on 400degree oven. is this a opportunity or the trend to continue.......
is this PANW a unicorn or pink sheet or what? didn't they released positive ER ? Why in falling knife mode, wow looks like over $80 down even after some early recovery. Bet even pink sheet unicorn companies do not exhibit such drama. what is the real scoop here - is it by any chance another pre squeeze game stop like case? or it is a political drama?
Patents Assigned to Oncolytics Biotech, Inc. till 2020, 2021-24 newly filed list not yet public
https://patents.justia.com/assignee/oncolytics-biotech-inc
2024 Outlook: Dr. Coffey: Looking ahead to 2024, we expect to initiate the first Phase 3 study for pelareorep in pancreatic cancer. The transition to a late-stage biopharmaceutical company will mark an important inflection point for investors, clinical collaborators and potential partners by providing a line of sight towards the path to regulatory approval and achieving our mission of developing pelareorep as an immunotherapeutic agent for cancer. We are excited to launch a new Phase 1/2 pancreatic cancer study investigating, for the first time, pelareorep in combination with modified FOLFIRINOX (mFOLFIRINOX). Finally, our discussions with regulators on a pivotal Phase 3 trial have been productive to date, and we expect to provide guidance on the registration path for metastatic breast cancer in the first half of 2024. We look forward to updating our stakeholders on our progress as the year unfolds."
Nvidia holding nearly 3.5 million shares in TuSimple Holdings (TSPH) - why?
are they buying TSPH TRUCKS?
QUAKE in spite of perfect results - must be power of WS manipulators from OUS
EARTHQUAKE
this could be $20 to $80 in a single day
there drug showing game changing result in pancreatic cancer in clinical trials - that is why so many big company now lined up behind
ACLS --> ALGM <-- LSCC
scratching a little, hoping one day this year will make 5k to 50k and more
claustrophobic
Long and strong Aeva holders enjoys life long tax write off - no worry for capital gain here.
ACLS ALGM
is some group or competitor going rogue against this company - guess they want them to fall under their knee. reached all time low even after producing continued earning beats.
man no downgrade - seems they are going to run it up -
APLD had Total Debt 103.97M and that is now reduced to $42.8 million. Total Revenue: $42.2 million, that is a 242% increase from the second quarter of 2023. Net Loss: $10.5 million, is a major improvement from a net loss of $26.8 million in the 2nd QQ of 2023.
Ended the quarter with $34.6 million in cash and equivalents.
seems market over reacted without considering the detail. of the 13M dump today, mostly retail and day trader. no institutional dump.
31.72% % of Shares Held by All Insider
54.30% % of Shares Held by Institutions
79.53% % of Float Held by Institutions
conclusion APLD doing good to better and - of course buying back is a better option during the next week or two volatility.
for now sold all apld with some profit.
strangely no downgrade - may show up latter
so low premarket volume suggests forced sell at lower SP, the premarket SP down likely to reverse in regular session
Consolidated Last Sale $6.11 -1.38 (-18.42%)
Pre-Market Volume 541,606
yap better than expected BTE Q-result is the key and market knows that and working accordingly, They turning and turning the spring and forming super coil, Now it will break below 5s or go-up beyond mesosphere. today is the last day for cheapies.
If they deliver BTE Q-result on the 16th then $25 before next Q- earning release - not unexpected. this may turn into a beast mode at some point starting next week. expect to see it crossing $100 by Dec 2024
Rigetti Superconducting & Superconducting transmon 2018 - 2022
RIGITTI quantum circuit and quantum logic gate-based model of computing.
Agave
Acorn
Aspen-1, -4, -7, -8,--9, -10, -11
Aspen-M-1, M-2, M-3
Whenever possible buying this at and below $10, in a year this going to be $100+, Qly rev. growth 400%+, every AI crypto block chain and everything in between need storage and APLD sitting at the center of that revolution and growing at reasonably fast speed.
What changed for such reaction today
nice MARA is up while BTC bigtime down.
Rigetti has portfolio of 165 patents - any chance they are coming out of dungeon dwelling this year.
from day one of inception till to date AEVA never gave real news -
winter everyday avalanche.
interesting, she sells and this goes up - is that a signal
BLOCKCHAIN play 2024
R they doing R/S if yes is it 1 for 2, 1 for 10, or 1 for 30
second how many new shares are they issuing post R/S, all 440M or less. AEVA need to be forthcoming. They are below $ since September 7th and trying hard to take above $1 but it is difficult till March? without R?S. Anyway 1 for 2 or 1 for 4 may be good. They are supposed to tell that on the week of 18th after the meeting but they did not. They did spend so much money in compensation and filing so many patents those do not have edge, most are west of money and will expire useless. other newcomers surpassing them fast with superior technology, appl most likely not considering them.
Result: Form 8-K 2023 Annual Meeting of AEVA Stockholders
Approved: to provide the Board of Directors with the right to decide at its discretion to effect a reverse stock split
Approved: securities issuances (up to 440M) for the purpose of complying with New York Stock Exchange rules.
PLTR
some how PLTR loosing charm, people switching banner
Form DEF 14A Aeva Technologies, Inc. For: Dec 18 RESULT?
Dec 18 meeting is over, where is the voting result -1 for 30 R/S or no R/S, 440M new shares to be issued post R/S or no 440M new shares.
algm : slow but steady rise eminent. 50 range very likely and then ADSK type move - great company without a doubt.
well doing thorough due diligence of this company's past and present - it is evident that sooner or latter PLTR going to be one of the new story stock like AAPL MSFT GOOG NVDA.
another company also going to do good though not in the same rank, but could go 10X is APLD
O K s it life coming to this stock or the board.
Is this a survivor or on other side.